


(19)  Canadian  
Intellectual Property  
Office

An Agency of  
Industry Canada

Office de la Propriété  
Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

(11) **CA 2 455 585**

(13) **A1**

(40) 20.02.2003

(43) 20.02.2003

(12)

(21) **2 455 585**

(51) Int. Cl.<sup>7</sup>: **A61K 31/425, A61P 43/00**

(22) **03.08.2002**

(85) **12.01.2004**

(86) **PCT/EP02/008691**

(87) **WO03/013521**

(30) **101 39 275.8 DE 10.08.2001**

(71) **BOEHRINGER INGELHEIM PHARMA GMBH & CO.  
KG,  
Binger Strasse 173, D-  
55216, INGELHEIM, XX (DE).**

(72) **MIERAU, JOACHIM (DE).  
PIEPER, MICHAEL PAUL (DE).  
LEHR, ERICH (DE).**

(74) **FETHERSTONHAUGH & CO.**

(54) **COMPOSES POUR LE TRAITEMENT DE L'ANHEDONIE**

(54) **COMPOUNDS FOR TREATING ANHEDONIA**

(57)

The invention relates to the use of dopamine  
antagonists for the production of medicaments to  
eliminate and/or relieve anhedonia.



Office de la Propriété  
Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2455585 A1 2003/02/20

(21) **2 455 585**

(12) **DEMANDE DE BREVET CANADIEN  
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2002/08/03  
(87) Date publication PCT/PCT Publication Date: 2003/02/20  
(85) Entrée phase nationale/National Entry: 2004/01/12  
(86) N° demande PCT/PCT Application No.: EP 2002/008691  
(87) N° publication PCT/PCT Publication No.: 2003/013521  
(30) Priorité/Priority: 2001/08/10 (101 38 275.8) DE

(51) Cl.Int.<sup>7</sup>/Int.Cl.<sup>7</sup> A61K 31/425, A61P 43/00  
(71) Demandeur/Applicant:  
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG,  
DE  
(72) Inventeurs/Inventors:  
LEHR, ERICH, DE;  
MIERAU, JOACHIM, DE;  
PIEPER, MICHAEL PAUL, DE  
(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : COMPOSES POUR LE TRAITEMENT DE L'ANHEDONIE  
(54) Title: COMPOUNDS FOR TREATING ANHEDONIA

(57) Abrégé/Abstract:

The invention relates to the use of dopamine antagonists for the production of medicaments to eliminate and/or relieve anhedonia.

**Canada**

<http://opic.gc.ca> • Ottawa-Hull K1A 0C9 • <http://cipo.gc.ca>

OPIC • CIPQ 191



**Abstract**

The invention relates to the use of dopamine agonists for preparing a pharmaceutical composition for overcoming and/or alleviating anhedonia.

78922pri.206

### Compounds for treating anhedonia

The invention relates to the use of dopamine agonists for preparing a  
5 pharmaceutical composition for overcoming and/or alleviating anhedonia.

#### Background to the invention

The term anhedonia is used in the prior art to denote a series of symptomatic  
conditions. Thus, the word anhedonia is used for example to denote loss of pleasure  
10 in life as well as an inability to derive any enjoyment from experiences or stimulations  
which normally give pleasure. Occasionally, anhedonia is divided into social  
anhedonia (for example the loss of pleasure in being with friends) and psychic  
anhedonia (for example the loss of pleasure in observing the beauty of nature). As a  
symptom anhedonia is found in psychiatric clinical pictures such as severe  
15 depression, schizophrenia and dependency diseases. It may possibly also occur as  
a result of serious stress and extreme situations.

#### Description of the invention

It has now been found that, surprisingly, dopamine agonists may usefully be used in  
20 therapeutically effective doses to overcome and/or alleviate anhedonia.

Accordingly, the present invention relates to the use of dopamine agonists for  
preparing a pharmaceutical composition for overcoming and/or alleviating  
anhedonia.

25

Preferably, the present invention relates to the use of dopamine agonists for  
preparing a pharmaceutical composition for overcoming and/or alleviating anhedonia  
in diseases of dependency.

30 By dependency diseases are meant within the scope of the present invention  
diseases or disorders of the state of health, which result from the physical and/or  
psychological dependency of an individual on drugs and/or medication, for example.  
Dependency on medication may arise for example as a result of regularly taking  
active substances, such as opiates, for example. Drug dependency may arise for  
35 example as a result of regularly taking heroin, cocaine, marijuana and the like. By  
drug dependency is also meant within the scope of the present invention physical  
and/or psychological dependency on alcohol, caffeine or nicotine by the regular  
consumption of alcoholic or caffeine-containing drinks and tobacco products.

By dependencies for the purposes of the present invention are also meant general, non-substance-related dependencies, such as may be observed for example in bulimia or addiction to exercise, etc.

5 The withdrawal of accustomed, rewarding triggers generally leads to a number of pathological psychophysiological reactions. Therapeutic approaches are known in the prior art in which attempts are made to substitute the original addiction triggers with other, less harmful substances. These are intended to alleviate the withdrawal without themselves leading to dependency. A more targeted approach is to analyse  
10 the symptoms of the dependency more precisely and then specifically to eliminate these. Admittedly, this is only treating the symptoms to begin with, but as a result of being freed from the craving for more addiction-producing agents over and over again the body is given the time it needs to recover in the longer term.

15 During withdrawal, states of excitement and restlessness as well as marked anhedonia occur in particular. Whereas attempts have already been made to treat the former with corresponding preclinical approaches, up till now there have been no suitable preclinical models for specifically treating anhedonia. This is where the present invention comes in: In a newly developed experiment it has been possible  
20 preclinically for the first time to make anhedonia probable in animals, and surprisingly the substances claimed have worked convincingly in this very model. They relieve the symptoms of anhedonia with a convincing degree of reproducibility at unusually low doses. Up till now such a convincing activity has not been detected with any other substance.

25

Preferred dopamine agonists which may be used within the scope of the present invention are selected from among pramipexole, talipexole, ropinirol, apomorphine, lisuride, terguride, pergolide, cabergoline, bromocriptine, ropinirol, (-)-quinpirol and (+)-7-OH-DPAT, optionally in the form of their enantiomers,  
30 optionally in the form of the pharmacologically acceptable acid addition salts thereof and optionally in the form of the hydrates and solvates thereof.

Particularly preferred dopamine agonists within the scope of their use according to the invention are selected from among pramipexole, talipexole and ropinirol,  
35 optionally in the form of their enantiomers, optionally in the form of the pharmacologically acceptable acid addition salts thereof and optionally in the form of the hydrates and solvates thereof.

Of exceptional importance within the scope of their use according to the invention are the dopamine agonists selected from pramipexole and talipexole, optionally in the form of their enantiomers, optionally in the form of the pharmacologically acceptable acid addition salts thereof and optionally in the form of the hydrates and  
5 solvates thereof.

Any reference to one of the abovementioned dopamine agonists includes a reference to any enantiomers of the compound in question which may exist. For example a reference to pramipexole also includes a reference to the (+)-enantiomer  
10 as well as the (-)-enantiomer. Within the scope of the present invention, however, the (-)-enantiomer is of particular importance.

The dopamine agonists which may be used according to the invention may optionally be used in the form of the pharmaceutically acceptable acid addition salts thereof as  
15 well as optionally in the form of its hydrates and/or solvates. By pharmaceutically acceptable acid addition salts of the dopamine agonists are meant according to the invention the salts selected from the salts of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid and maleic acid, of which the salts of  
20 hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid and acetic acid are particularly preferred. The salts of hydrochloric acid are particularly important.

In the case of pramipexole which is particularly preferably used according to the invention, the hydrochlorides are preferably used, pramipexole dihydrochloride  
25 being of particular significance. Of the hydrates of pramipexole, pramipexole dihydrochloride monohydrate is particularly preferred.

The dopamine agonists which may be used according to the invention may optionally be used in combination with other active substances. Preferred partners in the  
30 combination are compounds selected from the categories of the antidepressants, tranquillisers and sedatives. Synergistic effects in the intended activity mean that when combinations containing one of the additional active substances mentioned above as well as the dopamine agonists are used the dosage of the individual components is reduced.

35 The dosage of the dopamine agonists naturally depends to a great extent on the severity of the symptoms to be treated, on the one hand, and on the choice of active substance, on the other. For example, without restricting the present invention thereto, some possible doses will now be given, particularly for the compound

pramipexole which is particularly preferred according to the invention. This compound may be used in doses of about 0.05 to 3 mg, preferably 0.1 to 1.5 mg per day. These doses are based on pramipexole in the form of its free base. Based on the salt form pramipexole dihydrochloride monohydrate which is preferably used, the  
5 doses mentioned above correspond to about 0.07 to 4.26 mg, preferably 0.14 to 2.13 mg of pramipexole dihydrochloride monohydrate per day.

One possible dosing method, which is to be understood as being merely an illustrative example, is described below, based on pramipexole in the form of its free  
10 base: individual dosage titration at weekly intervals depending on activity and acceptability.

1st week: 1 tablet containing 0.088 mg of pramipexole 3 times a day;

2nd week: 1 tablet containing 0.18 mg of pramipexole 3 times a day;

3rd week and thereafter: 1/2 tablet containing 0.7 mg of pramipexole 3 times a day.

15

Within the scope of the use according to the invention the dopamine agonists may be administered orally, transdermally, intrathecally, by inhalation or parenterally. Suitable preparations include for example tablets, capsules, suppositories, solutions, syrups, emulsions, dispersible powders or patches. Regarding possible  
20 embodiments of a transdermal preparation which may be used according to the invention we now refer to the embodiments described by way of example in US 5112842, to which reference is hereby expressly made. Suitable tablets may be produced for example by mixing the active substance or substances with known excipients, for example inert diluents, such as calcium carbonate, calcium phosphate  
25 or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc, and/or agents for achieving delayed release such as carboxymethylcellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also consist of several layers.

30 The following are some examples of pharmaceutical preparations which may be used according to the invention. These are intended solely as an illustration without restricting the subject matter of the invention thereto.

**Tablet 1:**

Ingredients:		mg
<hr/>		
5	pramipexole dihydrochloride monohydrate	1.00
	mannitol	121.50
	maize starch	79.85
	highly dispersed silicon dioxide, anhydrous	2.30
	Polyvidone K25	2.35
10	magnesium stearate	3.00
Total		210.00

**Tablet 2:**

15	Ingredients:	mg
<hr/>		
	pramipexole	0.5
	mannitol	122.0
	maize starch, dried	61.8
20	maize starch	18.0
	highly dispersed silicon dioxide, anhydrous	2.4
	Polyvidone K25	2.3
	magnesium stearate	3.0
Total		210.0
25		

**Tablet 3:**

Ingredients:		mg
<hr/>		
30	pramipexole	0.25
	mannitol	61.00
	maize starch	39.90
	highly dispersed silicon dioxide, anhydrous	1.20
35	Polyvidone K25	1.15
	magnesium stearate	1.5
Total		105.00



**Tablet 4:**

Ingredients:		mg
<hr/>		
5	pramipexole	0.125
	mannitol	49.455
	maize starch dried	25.010
	maize starch	7.300
	highly dispersed silicon dioxide, anhydrous	0.940
10	Polyvidone K25	0.940
	magnesium stearate	1.230
<hr/>		
	Total	85.000

**15 Solution for injection:**

	pramipexole dihydrochloride monohydrate	0.3 mg
	sodium chloride	0.8 mg
	benzalkonium chloride	0.01 mg
20	water for injections ad 100 ml	

**Patent Claims**

- 1) Use of dopamine agonists for preparing a pharmaceutical composition for overcoming and/or alleviating anhedonia.
- 5 2) Use according to claim 1 for preparing a pharmaceutical composition for overcoming and/or alleviating anhedonia in dependency diseases.
- 10 3) Use according to one of claims 1 or 2, characterised in that one or more, preferably one dopamine agonist selected from among pramipexole, talipexole, ropinirol, apomorphine, lisuride, ferguride, pergolide, cabergoline, bromocriptine, ropinirol, (-)-quinpirol and (+)-7-OH-DPAT, is or are used, optionally in the form of their enantiomers, optionally in the form of the pharmacologically acceptable acid addition salts thereof and optionally in the form of the hydrates and solvates thereof.
- 15 4) Use according to claim 3, wherein the dopamine agonist is selected from among pramipexole, talipexole and ropinirol, optionally in the form of their enantiomers, optionally in the form of the pharmacologically acceptable acid addition salts thereof and optionally in the form of the hydrates and solvates thereof.
- 20

Fetherstonhaugh & Co.  
Ottawa, Canada  
Patent Agents